These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 23777659

  • 1. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [Abstract] [Full Text] [Related]

  • 2. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M, Zhao L, Shen D, Li X, Wang J, Wei L.
    Chin Med J (Engl); 2014 Sep; 127(8):1459-63. PubMed ID: 24762589
    [Abstract] [Full Text] [Related]

  • 3. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct 18; 43(5):743-8. PubMed ID: 22008688
    [Abstract] [Full Text] [Related]

  • 4. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J, Xie L, Luo X, Yang B, Zhang H, Zhu Q, Chen X.
    J Gynecol Oncol; 2019 Jan 18; 30(1):e13. PubMed ID: 30479097
    [Abstract] [Full Text] [Related]

  • 5. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H.
    Gynecol Oncol; 2009 Mar 18; 112(3):537-42. PubMed ID: 19108875
    [Abstract] [Full Text] [Related]

  • 6. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Werner HMJ, Amant F, Massuger LFAG, Pijnenborg JMA.
    Int J Gynecol Cancer; 2018 Mar 18; 28(3):514-523. PubMed ID: 29324536
    [Abstract] [Full Text] [Related]

  • 7. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L, Kubiak R, Pasz-Walczak G, Sek P, Piekarski J, Szwalski J, Spych M, Chałubińska-Fendler J, Suzin J, Tyliński W, Jeziorski A.
    Ginekol Pol; 2013 Feb 18; 84(2):95-101. PubMed ID: 23668054
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K, Fukuda K, Hachisuga T, Mori M, Uchiyama M, Iwasaka T, Sugimori H.
    Gynecol Oncol; 1999 Mar 18; 72(3):351-9. PubMed ID: 10053107
    [Abstract] [Full Text] [Related]

  • 9. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
    Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H.
    J Cancer Res Clin Oncol; 2004 Mar 18; 130(3):161-8. PubMed ID: 14689303
    [Abstract] [Full Text] [Related]

  • 10. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D.
    Eur J Gynaecol Oncol; 2001 Mar 18; 22(2):122-6. PubMed ID: 11446475
    [Abstract] [Full Text] [Related]

  • 11. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S.
    Gynecol Oncol; 2012 Jan 18; 124(1):15-20. PubMed ID: 21864888
    [Abstract] [Full Text] [Related]

  • 12. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF, Tang QL, Shen XM, Li HG, Chen LH, Wang XY, Luo X, Lin ZQ, Jiang GY.
    Pathol Res Pract; 2012 Dec 15; 208(12):730-5. PubMed ID: 23122929
    [Abstract] [Full Text] [Related]

  • 13. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ.
    Hum Pathol; 1998 Jun 15; 29(6):551-8. PubMed ID: 9635673
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C, Wejaranayang C, Vipupinyo C.
    J Med Assoc Thai; 2008 Dec 15; 91(12):1779-84. PubMed ID: 19133508
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K, Tel N, Ozalp SS, Yalcin OT, Yilmaz V.
    Eur J Gynaecol Oncol; 2002 Dec 15; 23(6):540-4. PubMed ID: 12556100
    [Abstract] [Full Text] [Related]

  • 16. Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.
    Tangjitgamol S, Tanvanich S, Srijaipracharoen S, Manusirivithaya S.
    Histol Histopathol; 2013 Jun 15; 28(6):787-94. PubMed ID: 23255089
    [Abstract] [Full Text] [Related]

  • 17. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX.
    Asian Pac J Cancer Prev; 2015 Jun 15; 16(2):823-9. PubMed ID: 25684532
    [Abstract] [Full Text] [Related]

  • 18. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
    González-Rodilla I, Aller L, Llorca J, Muñoz AB, Verna V, Estévez J, Schneider J.
    Anticancer Res; 2013 Nov 15; 33(11):5091-5. PubMed ID: 24222154
    [Abstract] [Full Text] [Related]

  • 19. Evolution in endometrial cancer: evidence from an immunohistochemical study.
    Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen L, Moerman P, Vergote I, Salvesen H, Amant F.
    Int J Gynecol Cancer; 2011 Feb 15; 21(2):316-22. PubMed ID: 21734474
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H.
    Gynecol Oncol; 1998 Jun 15; 69(3):220-5. PubMed ID: 9648591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.